Close Window

Digital Look Email A Friend

FDA extends review period of GSK blood cancer drug momelotinib

Published by Michele Maatouk on 16th June 2023

(Sharecast News) - GSK said on Friday that the US Food and Drug Administration has extended the review period of its new drug application for momelotinib, which is used to treat a blood cancer called myelofibrosis.

URL: http://www.digitallook.com/dl/news/story/33577925/...

Email this article to your friends
NOTE: These email addresses will be used to email the information on your behalf and will not be collected by Digital Look for any marketing purposes.